

we move ideas

PROT@GEN[®]

Protagen at a Glance

► Areas of Activity

GMP compliant Protein Analysis, Stability Testing and Bioassays; Development of Serum based Diagnostics; Development and Production of Protein Microarrays; Solutions in Bioinformatics

► Number of Employees: 36

► Founded: 1997

► Ownership: Private

► Management Board

Dr. Stefan Müllner, CEO
Martin Blüggel, COO
Dr. Peter Schulz-Knappe, CSO

► Investors

S-Venture Capital Dortmund GmbH
S-Capital Dortmund GmbH & Co. KG
MIG AG & Co. KG Beteiligungsfonds 1, 3 and 9
KfW Bankengruppe

► Board of Directors

Prof. Axel Kleemann (Chairman)
Prof. Theodor Dingeramn
Holger Clemens Hinz
Michael Motschmann
Dr. Thomas Schweins
Gerhard Steinkamp

► External Collaborations

Biogenes GmbH, Berlin; Ruhr University Bochum (Medical Proteome Center, Neurological Clinic); University of Applied Sciences, Bonn-Rhein-Sieg; University of Düsseldorf (Rheumatology Department and Children's Oncology); University of Duisburg-Essen (Departments for Neurology and Psychiatry); University Regensburg (Department for Clinical Chemistry and Laboratory Medicine); Klinikum Luedenscheid (Department for Neurology); Oridis Biomed GmbH, Graz; University of Innsbruck (Departments for Urology and Gynecology); Karolinska Institute Stockholm (Department for Oncology); John Hopkins University, Baltimore MD, USA (Department for Urology)

► Contact

Dr. Stefan Müllner, CEO

Protagen AG
Otto-Hahn-Str. 15
44227 Dortmund
Germany

Phone: +49 231 9742 6300
Fax: +49 231 9742 6301
Email: info@protagen.de
Web: www.protagen.com

March 2010

Company Profile

Protagen AG, located in Dortmund, Germany, is an international leading specialist in the fields of diagnostics and GMP-compliant protein analysis. The Company has a decade of experience in applying the most advanced protein research tools and techniques to improve the efficiency of drug discovery and drug development processes. In addition, Protagen serves customers in all areas of Life Sciences.

Products and Services

Protein Services

Protagen provides GMP compliant services for protein characterization and bioassays as well as stability and release testing of biotherapeutics. In addition, Protagen is specialized in customized method development for protein analysis and proteome studies in all areas of Life Sciences. Protagen employs state-of-the-art bioinformatic technologies and sophisticated instrumentation to match all customer needs and current regulatory requirements. Protagen develops and markets software products like Modiro™ - The PTM-Explorer which enables the rapid, automated detection and analysis of true post-translational modifications (PTMs) in proteins and offers bioinformatics services in all areas of protein analysis.

Diagnostics

As an innovator in protein microarrays, Protagen has developed the proprietary UNIarray® technology platform for the development of novel, serum based diagnostics. UNIarray® allows the systematic identification of proprietary auto-antibody signatures in blood for the development of new *in-vitro* diagnostics and companion diagnostics for patient stratification and

Protagen AG

therapy selection. In addition, Protagen has developed the UNIchip® family of protein microarrays for faster development of diagnostic and therapeutic antibodies or other protein binders.

Technologies applied

- GMP/ICH guidelines compliant protein analyses
- MALDI- and LC-ESI-based protein mass spectrometry
- Gel-based and non-gel-based differential protein display
- Bioassays for activity testing of biotherapeutics
- Exploratory protein analysis and proteome studies
- Protein Bioinformatics
- PTM detection software Modiro™
- Protein Production
- High throughput protein expression and purification platform
- UNIchip® family of protein microarrays for antibody validation and stability testing
- UNIarray® technology platform for the development of diagnostics

More information at www.protagen.com



www.protagen.com